Study Title

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer

Study Details

Description:

Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Contacts:

Erin Schubert, BA

erin.schubert@pennmedicine.upenn.edu

215-573-6569

Ashley Veronsky, BA

ashley.veronsky@pennmedicine.upenn.edu

215-898-4346